Nutcracker Therapeutics’ Post

Antibody drug conjugates (ADCs) are revolutionizing the treatment landscape for cancer by targeting specific proteins on the surface of cancer cells and delivering a toxic payload directly to the tumor. The accelerated development of ADCs in recent years reflects the industry’s heighted interest in this groundbreaking approach and commitment to advance precision medicine. This Cancer Discovery article explores the surge of investments in ADCs, including perspectives from our CEO Kenneth Galbraith about Zymeworks’ approach to highly differentiated ADC therapeutics. Read here: https://lnkd.in/e63wNiij

Accelerate cancer therapy development with Promega's advanced bioassay technology! CD47/SIRPα interaction is an example of immune checkpoint, where myeloid cells evade T cell activity. Preclinical studies are developing molecules that are able to block CD47-SIRPα interactions and lead to targeted tumor killing. Thanks to the powerful Nanoluc® reporter, Promega released specific cell-based bioassays for the assessment of potency and stability of Biologics blocking the interaction. Read more at: https://lnkd.in/ekRYR4Z7

Syngeneic mouse models of mammary carcinoma are an important option for preclinical testing of novel immuno-oncology agents that require an intact immune system to elicit activity. Labcorp’s highly metastatic 4T1-Luc2-1A4 mammary carcinoma model shows equivalent orthotopic growth kinetics in immune-deficient strains and immuno-competent Balb/c mice reflecting a weakly immunogenic tumor. This model is refractory to checkpoint inhibitor therapy but has some response to focal radiation, which allows for an ample therapeutic window to combine with novel therapies. We have also developed the 4T1-Luc2-1A4 model in a 3D reconstructed mouse breast (r-mBreast) matrix providing an early opportunity to identify successful drug candidates. This model has been well characterized with extensive immune profiling and is available for client-sponsored studies. Learn more:

Syngeneic mouse models of mammary carcinoma are an important option for preclinical testing of novel immuno-oncology agents that require an intact immune system to elicit activity. Labcorp’s highly metastatic 4T1-Luc2-1A4 mammary carcinoma model shows equivalent orthotopic growth kinetics in immune-deficient strains and immuno-competent Balb/c mice reflecting a weakly immunogenic tumor. This model is refractory to checkpoint inhibitor therapy but has some response to focal radiation, which allows for an ample therapeutic window to combine with novel therapies. We have also developed the 4T1-Luc2-1A4 model in a 3D reconstructed mouse breast (r-mBreast) matrix providing an early opportunity to identify successful drug candidates. This model has been well characterized with extensive immune profiling and is available for client-sponsored studies. Learn more:

Syngeneic mouse models of mammary carcinoma are an important option for preclinical testing of novel immuno-oncology agents that require an intact immune system to elicit activity. Labcorp’s highly metastatic 4T1-Luc2-1A4 mammary carcinoma model shows equivalent orthotopic growth kinetics in immune-deficient strains and immuno-competent Balb/c mice reflecting a weakly immunogenic tumor. This model is refractory to checkpoint inhibitor therapy but has some response to focal radiation, which allows for an ample therapeutic window to combine with novel therapies. We have also developed the 4T1-Luc2-1A4 model in a 3D reconstructed mouse breast (r-mBreast) matrix providing an early opportunity to identify successful drug candidates. This model has been well characterized with extensive immune profiling and is available for client-sponsored studies. Learn more:

Syngeneic mouse models of mammary carcinoma are an important option for preclinical testing of novel immuno-oncology agents that require an intact immune system to elicit activity. Labcorp’s highly metastatic 4T1-Luc2-1A4 mammary carcinoma model shows equivalent orthotopic growth kinetics in immune-deficient strains and immuno-competent Balb/c mice reflecting a weakly immunogenic tumor. This model is refractory to checkpoint inhibitor therapy but has some response to focal radiation, which allows for an ample therapeutic window to combine with novel therapies. We have also developed the 4T1-Luc2-1A4 model in a 3D reconstructed mouse breast (r-mBreast) matrix providing an early opportunity to identify successful drug candidates. This model has been well characterized with extensive immune profiling and is available for client-sponsored studies. Learn more:

SIRPα is a transmembrane protein predominantly expressed on myeloid cells. It interacts with CD47, a protein often referred to as the "don't eat me" signal, which is expressed on the surface of various cells, including cancer cells. This interaction inhibits the phagocytosis of cells by macrophages, allowing cancer cells to evade the immune system. Current methods for assessing the activity of SIRPα/CD47 checkpoint inhibitors rely on primary monocyte-derived macrophages and direct measurement of phagocytosis. These assays are laborious and highly variable due to their reliance on donor cells, complex assay protocols and unqualified assay reagents. #Promega 's SIRPα/CD47 Blockade Bioassay is a bioluminescent reporter cell-based assay designed to measure potency and stability of Biologics that bind and block SIRPα/CD47 interactions without the need of cultured primary cells, providing significant time and labor savings. More at: https://lnkd.in/eE_yAkH5 #SIRPα/CD47 #Bioassays #potency Promega Switzerland

Atossa Therapeutics announces an expanded research agreement with Weill Cornell Medicine to explore the potential synergy between antibody drug conjugates (ADCs) and (Z)-endoxifen. Previous in silico and preclinical research determined a strong, clinically relevant, anti-tumor effect when combining the two therapies. “The work we are doing with Weill Cornell is designed to validate the in silico modeling in well-established cell culture models of breast cancer. Once we have this data, we expect to move quickly into a clinical study investigating a (Z)-endoxifen / ADC combination in patients with late-line metastatic breast cancer,” said Dr. Steven Quay, Atossa’s President and Chief Executive Officer. Learn more: https://lnkd.in/ekad_hWY #clinicaltrial #breastcancer, https://lnkd.in/ev6gadb7

Look back at the AACR Journals 2023! Did you know that Molecular Cancer Therapeutics serves as a central hub for first disclosures in cancer? First Disclosures present drugs for the first time in published literature, accompanied by pertinent translational investigations and a graphical abstract to enhance dissemination of the findings. Read the timely, novel drug disclosures already published and learn how to submit your small-molecule drug, antibody, vaccine, or viral and cellular therapy study. https://bit.ly/3v8Ydks

Monoclonal antibodies set the stage, but the next wave is here—bispecific antibodies (bsAbs). These marvels enhance specificity and potency by binding two different antigens or epitopes and over 85% of bsAbs in clinical trials are dedicated to cancer therapeutics. In this Application Note, Sino Biological, Inc. Biological explores emerging bsABbs in the discovery, development, preclinical, and clinical stages and their targets in cancer immunotherapy. Read now! >>> https://bit.ly/48BMFow